Rituximab Maintenance Therapy for Granulomatosis with Polyangiitis

Rationale for Rituximab Maintenance Therapy

• The American College of Rheumatology recommends rituximab as a first-line maintenance therapy for Granulomatosis with Polyangiitis (GPA) after remission induction, with strong evidence supporting its superiority over other agents in preventing disease relapse 1, 2, 3
• The MAINRITSAN trial demonstrated that rituximab maintenance therapy (500mg every 6 months) significantly reduced relapse rates compared to azathioprine in GPA patients 4, 3
• The RITAZAREM trial confirmed rituximab's superior efficacy for maintenance therapy in relapsing disease 3
• Current guidelines specifically recommend rituximab as maintenance therapy for GPA with a scheduled dosing protocol of 500mg at complete remission and then every 6 months (24 weeks) 2

Appropriate Dosing and Administration

• The KDIGO guidelines recommend a dosing schedule of 500mg at complete remission and then at months 6, 12, and 18 (MAINRITSAN scheme) 2
• This dosing schedule (500mg every 6 months) has been shown to effectively maintain remission while minimizing adverse effects 5, 2
• The planned 3 visits within 1 year corresponds to the standard maintenance protocol for rituximab in GPA 2, 3

Monitoring and Safety Considerations

• The patient is appropriately receiving Bactrim prophylaxis while B-cells are depleted, which is consistent with best practices for infection prevention 6